מחיר ריאלי לרכישת החברה במלואה: Illumina, Inc. (ILMN)

Illumina, Inc. (ILMN) generates revenue from the sale of DNA sequencing systems, where the primary profit is driven by recurring purchases of proprietary reagents. Despite the narrow specialization of the equipment, industry leadership and a stable payment stream mitigate the risks associated with a single-product focus. Strategic alliances with pharmaceutical laboratories are accelerating the development of cancer diagnostic tests. This daily price chart on GURU.Markets reflects an Enterprise Value of 44966.29.

Enterprise value combines market capitalization and net debt, allowing an investor to assess the actual cost of a full asset buyout regardless of speculative fluctuations. By analyzing the total value inclusive of debt, one can determine the extent to which the monopoly sequencing ecosystem of Illumina, Inc. (ILMN) is capable of servicing its obligations and maintaining a high business valuation even after the forced divestiture of Grail.